This bill seeks to amend the Foreign Assistance Act of 1961 to strengthen global efforts against tuberculosis (TB). It recognizes the continuing challenge of TB's international spread and deadly impact, emphasizing the need for additional tools and resources for effective diagnosis, prevention, and treatment. The legislation asserts that well-resourced TB programs can also serve as a critical platform for responding to future infectious airborne and respiratory disease pandemics. The policy objectives include helping to end the TB public health emergency by accelerating actions to support the diagnosis and treatment of all forms of TB and prevent new infections. The United States will prioritize reducing mortality, incidence, and health costs by supporting innovative new technologies , expanding diagnosis and treatment for at-risk individuals, and ensuring high-quality TB care. This also involves sustainable procurement of TB commodities and avoiding those of unknown quality or excessive cost. The bill authorizes the President to furnish assistance for TB prevention, treatment, control, and elimination, prioritizing the building and strengthening of TB programs to increase diagnosis and treatment access. It emphasizes direct, high-quality care for all forms of TB, including drug-resistant strains (MDR-TB, XDR-TB), and research into innovative diagnostics, therapies, and vaccines. The legislation establishes specific goals for 2027-2030, aiming to reduce TB incidence by 80% and mortality by 90% from 2015 levels, and to ensure high rates of diagnosis, treatment initiation, and success, alongside providing preventive treatment to 30 million individuals. Furthermore, the bill mandates coordination with partner nations, international organizations, and the private sector to develop a comprehensive global TB response. Bilateral assistance will catalyze support for research and development of new tools and ensure programs focus on active case finding and cost-effective diagnosis and treatment. The legislation requires annual reports to Congress on United States foreign assistance activities and TB research and development progress until 2032, with a Government Accountability Office evaluation report due within four years. This act will cease to have effect on January 1, 2033.